What Makes a Peptide Novel?
TL;DR: A “novel” peptide is a genuinely new amino-acid sequence, rather than one of the handful discovered decades ago that most vendors resell. Novelty is checked against known-sequence databases, and it is the foundation of AI peptide design. Everything Velox supplies is a research reagent for in vitro use only.
Every vendor sells the same handful of peptides discovered decades ago. "Novel" peptides are genuinely new sequences — here is what that means, how novelty is checked, and why it is the foundation of AI peptide design.
A peptide is a sequence — and the sequence is everything
A peptide is a short chain of amino acids. The order of those amino acids — the sequence — determines its shape, charge, stability and behaviour. Change one building block and you can change everything about how the molecule folds and acts.
That is why "novelty" in peptides is really a question about sequences: has this exact chain of building blocks been described before, or is it genuinely new?
What "novel" actually means
A novel peptide is one whose sequence does not match a known, catalogued compound. Most peptides sold by vendors are decades old — BPC-157, GHK-Cu, Semax and the like were all characterised long ago. A novel sequence is one that has not been previously published or made commercially available.
Novelty is not the same as "better". A novel candidate is an untested hypothesis — a starting point for in-vitro research, not a validated compound. The value of novelty is that it opens design space that the standard catalogue does not cover.
How novelty is checked
A sequence can be compared against a reference set of known peptides. If it closely matches an existing entry, it is "known". If it is clearly different, it is flagged as likely novel; partial overlaps sit in between.
Velox Design Lab runs this check on every candidate it generates, so each design is labelled novel, partially similar, or already-existing before you commit to synthesising it.
Why length and synthesisability matter
Two practical properties shape whether a novel sequence is worth pursuing: length-optimisation (shorter, well-formed chains are cheaper and more reliable to make) and synthesisability (some residues and patterns are far easier to synthesise than others).
A genuinely useful design balances novelty with these constraints — new enough to be interesting, practical enough to actually make. See our reconstitution guide for what happens after a peptide is made.
Why the same peptides keep getting resold
Walk any research-peptide catalogue and you see the same names: BPC-157, TB-500, GHK-Cu, Semax, CJC-1295. There is a simple reason. These sequences were characterised decades ago, their synthesis routes are well understood, and — crucially — no one owns them, so any manufacturer can make and sell them without designing anything new.
That makes the standard catalogue cheap and reliable, but it also means the entire market clusters around a small pool of old chemistry. Genuinely new sequences are rare because designing one from scratch has historically needed specialist medicinal-chemistry knowledge. Novelty checking, and the AI design tools built on top of it, exist to open up the space beyond that resold handful — to let a researcher explore sequences that no vendor happens to already stock.
Novelty is a starting point, not a verdict
It is worth repeating that a novel label says nothing about whether a sequence works, is safe, or is useful. It says only that the exact chain has not been catalogued before. A novel candidate is an untested computational hypothesis — a prompt for in vitro investigation by a qualified researcher, never a therapeutic and never a subject for human or veterinary use.
In practice, novelty is most useful as a filter. When a design overlaps a well-characterised compound, it is usually faster and cheaper to study the known material directly; when it is genuinely new, you at least know you are exploring ground the standard catalogue does not cover. Either way the sequence still has to be synthesised, purified and evaluated on the bench before it means anything. If you are new to the field, our explainer on what research peptides are puts this in context.
